Skip to Main Content

Paper Details

Prevalence of immune-related adverse events and anti-tumor efficacy in advanced/metastatic urothelial carcinoma following immune-checkpoint inhibitor treatment.
Clin Transl Oncol
1
2023
Author NameAffiliation
Joaquin MateoVall d'Hebron Institute of Oncology, Vall d' Hebron University Hospital, Universitat Autonoma de Barcelona
  • 1 - 1

Datasets

Release 1.2